Clinical Trial Update: Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating predictive markers for toxicity and efficacy in patients with clear-cell metastatic renal cell carcinoma treated with anti-VEGF thera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Metastatic Renal Cell Carcinoma

Snippet

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Conditions: Clear-cell Metastatic Renal Cell Carcinoma | Phase 4 | Status: TERMINATED